Eisai Co., Ltd.
OTC: ESALY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Haruo Naito
- Employees
- 11,092
- Headquarters
- Tokyo, Japan
- IPO year
- 1995
- Market cap
- $17.6B
- Website
- https://www.eisai.co.jp
Loading ESALY…
Loading profile data…Frequently asked questions about ESALY
What does Eisai Co., Ltd. (ESALY) do?
Headquartered in Tokyo, Japan, Eisai Co., Ltd. is a pharmaceutical company that develops and markets a diverse range of medicinal products within Japan. Its extensive product lineup includes treatments for neurological conditions, such as Aricept for Alzheimer's disease and Lewy body dementia, Methycobal for peripheral neuropathy, and Fycompa, a...
Where does ESALY trade?
Eisai Co., Ltd. (ESALY) trades on the Other OTC.
What sector is ESALY in?
Eisai Co., Ltd. (ESALY) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Eisai Co., Ltd.?
Haruo Naito is the chief executive officer of Eisai Co., Ltd. (ESALY).
Where is Eisai Co., Ltd. headquartered?
Eisai Co., Ltd. is headquartered in Japan.
Does ESALY pay a dividend?
Yes — Eisai Co., Ltd. (ESALY) paid a trailing twelve-month dividend of USD 19.23 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did ESALY go public?
Eisai Co., Ltd. (ESALY) completed its initial public offering in 1995.
Is ESALY an ADR?
Yes — ESALY is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Eisai Co., Ltd. reporting and dividends follow the underlying issuer.